Early switch from run-in with targeted to immunotherapy in advanced BRAF(V600)-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial
在BRAF(V600)阳性晚期黑色素瘤中,早期从靶向治疗过渡到免疫治疗:随机II期ImmunoCobiVem试验的最终结果
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105053
Livingstone, E; Gogas, H J; Kandolf, L; Meier, F; Eigentler, T K; Ziemer, M; Terheyden, P; Gesierich, A; Herbst, R A; Kähler, K C; Ziogas, D C; Mijušković, Ž; Garzarolli, M; Garbe, C; Roesch, A; Ugurel, S; Gutzmer, R; Gaudy-Marqueste, C; Kiecker, F; Utikal, J; Hartmann, M; Miethe, S; Eckhardt, S; Zimmer, L; Schadendorf, D